Overview

* Replimune ( REPL ) fiscal Q1 net loss widens to $86.7 mln from $53.8 mln yr ago

* Company's cash position decreased to $403.3 mln due to clinical development costs

Outlook

* Replimune expects cash to fund operations into Q4 2026

Result Drivers

* R&D EXPENSES - Increased due to scaling operations for RP1 commercial launch and higher personnel-related costs

* SG&A EXPENSES - Rose significantly due to increased personnel and stock-based compensation costs

* CASH DECREASE - Cash position fell due to clinical development costs and operating activities

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 Net -$86.69

Income mln

Q1 Basic -$0.95

EPS

Q1 Cash $403.30

& mln

Investme

nts

Q1 $90.42

Operatin mln

g

Expenses

Q1 -$90.42

Operatin mln

g Income

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)